The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations.
- DOI
- 10.1080/14796694.2024.2376521
- Published
- 2024
- Container
- Future oncology (London, England)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/14796694.2024.2376521,
title = {The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations.},
author = {George S and Blay JY and Chi P and Jones RL and Serrano C and Somaiah N and Gelderblom H and Zalcberg JR and Reichmann W and Sprott K and Cox P and Sherman ML and Ruiz-Soto R and Heinrich MC and Bauer S},
year = {2024},
journal = {Future oncology (London, England)},
doi = {10.1080/14796694.2024.2376521},
url = {https://doi.org/10.1080/14796694.2024.2376521}
}RIS
TY - JOUR TI - The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations. AU - George S AU - Blay JY AU - Chi P AU - Jones RL AU - Serrano C AU - Somaiah N AU - Gelderblom H AU - Zalcberg JR AU - Reichmann W AU - Sprott K AU - Cox P AU - Sherman ML AU - Ruiz-Soto R AU - Heinrich MC AU - Bauer S PY - 2024 JO - Future oncology (London, England) DO - 10.1080/14796694.2024.2376521 UR - https://doi.org/10.1080/14796694.2024.2376521 ER -
APA
S, G., JY, B., P, C., RL, J., C, S., N, S., H, G., JR, Z., W, R., K, S., P, C., ML, S., R, R., MC, H., & S, B. (2024). The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations.. Future oncology (London, England). https://doi.org/10.1080/14796694.2024.2376521
Source records
- pubmed · retrieved 2026-09-26T23:01:59.616Z